Toxicities of CD19 CAR‐T cell immunotherapy
نویسندگان
چکیده
منابع مشابه
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.
UNLABELLED The CD19 antigen, expressed on most B-cell acute lymphoblastic leukemias (B-ALL), can be targeted with chimeric antigen receptor-armed T cells (CART-19), but relapses with epitope loss occur in 10% to 20% of pediatric responders. We detected hemizygous deletions spanning the CD19 locus and de novo frameshift and missense mutations in exon 2 of CD19 in some relapse samples. However, w...
متن کاملCD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer and the prognosis of children with relapsed or therapy refractory disease remains a challenge. Treatment with chimeric antigen receptor-modified T cells targeting the CD19 antigen (CART-19 therapy) has been presented as a promising approach toward improving the outcome of relapsed or refractory disease. However, 10%-2...
متن کاملApproaches to Improve Clinical Efficacy of CD19-Redirected Chimeric Antigen Receptor (CD19 CAR) T Cell Immunotherapy of Non-Hodgkin’s Lymphoma
Clinical use of CD19-redirected chimeric antigen-receptor (CD19 CAR) T cell therapy has shown promise in the treatment of various B cell malignancies including acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL). However, its clinical use is limited due to inherent or acquired resistance of tumor cells to apoptotic death signals delivered by CAR transduced T cells as well as by ...
متن کاملT cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies
T cells expressing chimeric antigen receptors (CARs) or the infusion of bispecific T-cell engagers (BITEs) have shown antitumor activity in humans for CD19-positive malignancies. While BITEs redirect the large reservoir of resident T cells to tumors, CAR T cells rely on significant in vivo expansion to exert antitumor activity. We have shown that it is feasible to modify T cells to secrete soli...
متن کاملImmunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5
Using genetic engineering a humanized Fab fragment with specificity for CD19 was fused to a disulfide-stabilized single-chain antibody (dsFv) recognizing CD5. This format should show reduced immunogenicity and improved tissue penetration. The specificity of bsAb FabCD19xdsFvCD5 binding to target cells was verified by flow cytometry on B and T lymphoma cell lines. Binding affinities of both arms...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2019
ISSN: 0361-8609,1096-8652
DOI: 10.1002/ajh.25445